Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Clinical Data, a biotechnology company, has announced that its PGxHealth division has launched a new genetic test for arrhythmogenic right ventricular cardiomyopathy, an inherited and often fatal heart condition.
Subscribe to our email newsletter
The Familion arrhythmogenic right ventricular cardiomyopathy (ARVC) test is a complex genetic test that sequences the five genes most commonly associated with ARVC (PKP2, DSP, DSG2, DSC2 and TMEM43) and is performed in a CLIA-certified commercial laboratory that meets all applicable state and federal guidelines, said Clinical Data.
The test will help clinicians interpret borderline clinical findings, confirm the clinical suspicion of ARVC, make presymptomatic diagnoses, identify silent carriers and enable informed genetic counseling, the company added.
In addition, PGxHealth intends to publish its Familion databases beginning in the spring of 2009, as part of a large-scale database project for inherited cardiac conditions. Initially, the publicly accessible data will include information related to long QT syndrome and Brugada syndrome, two inherited channelopathies.
Drew Fromkin, president and CEO of Clinical Data, said: “The launch of our Familion ARVC test illustrates the company’s ongoing commitment to extend our leadership position in cardiovascular genetics by making additional tests more broadly available to clinicians, patients and their family members.”